Drug intelligence / Profile preview

Primodil-L

Development stage
Phase 4
Lead developer
Medley
Modality
Small Molecules
Administration
Oral
01

Overview

Primodil-L is a fixed-dose combination tablet containing the calcium channel blocker amlodipine (5 mg) and the angiotensin II receptor blocker (ARB) losartan potassium (50 mg). Developed by Medley, it is approved for the treatment of hypertension, particularly in patients with associated nephropathy or those requiring dual therapy to achieve blood pressure control. Amlodipine works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Losartan selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone secretion. Together, these complementary mechanisms effectively lower blood pressure, reduce cardiac workload, and help protect renal function.

Brand names
Primodil-L
Other names
amlodipine + losartanamlodipine and losartanlosartan + amlodipinelosartan and amlodipine
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on Primodil-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primodil-L.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call